Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05777031 · ClinicalTrials.gov registry record · Phase 4

Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease

A Phase 4 study of Genital Diseases, Male and Peyronie Disease, sponsored by University of Miami.

Recruiting
Registry status
Phase 4
Development phase
22
Enrollment target
2
Study locations

NCT05777031 is a Phase 4 study of Genital Diseases, Male and Peyronie Disease that is actively recruiting participants, run by University of Miami. The registered enrollment target is 22 participants, below the 70-participant average among 4 other Genital Diseases, Male trials with a reported enrollment target (69% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05777031, a Phase 4 study of Genital Diseases, Male and Peyronie Disease, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
Phase 4
Development phase
22 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to learn about the safety and side effects of intralesional collagenase clostridium histolyticum (CCH) injected into the Peyronies Disease (PD) plaque after receiving prior treatment with intralesional Platelet Rich Plasma (PRP) injections.

Interventions

  • DRUG Collagenase Clostridium Histolyticum (CCH)

Study Locations (2)

Florida

  • University of Miami - Desai Sethi Urology Institute - Miami
  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2023-10-02
Est. Completion 2027-01-15
Phase Phase 4

Sponsor

University of Miami

721 total trials

What the Registry Record Tells You About NCT05777031

The ClinicalTrials.gov registry entry for NCT05777031 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 70-participant average among 4 other Genital Diseases, Male trials with a reported enrollment target (69% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Genital Diseases, Male appearing as the primary indexed condition, and to 1 intervention - of which Collagenase Clostridium Histolyticum (CCH) is the first listed.

NCT05777031 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT05777031 about?

NCT05777031 is a clinical study titled "Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease". The purpose of this study is to learn about the safety and side effects of intralesional collagenase clostridium histolyticum (CCH) injected into the Peyronies Disease (PD) plaque after receiving prior treatment with intralesional Platelet Rich Plasma (PRP) injections.

What is the current status of trial NCT05777031?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2023-10-02. Estimated completion is 2027-01-15.

What conditions does trial NCT05777031 study?

This clinical trial studies the following conditions: Genital Diseases, Male, Peyronie Disease, Sexual Dysfunctions, Psychological.

What interventions are being tested in trial NCT05777031?

The interventions under investigation include: Collagenase Clostridium Histolyticum (CCH) (DRUG).

Who is sponsoring clinical trial NCT05777031?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05777031 being conducted?

This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Genital Diseases, Male

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.